Prognostic markers of COPD. Role of comorbidity;Marcadores pronósticos en la EPOC. Papel de la comorbilidad

Archivos de Bronconeumologia

Volumn 45, Issue SUPPL.5, 2009, Pages 2-7

  Álvarez, Felipe Villar ^a   Romero, Germán Peces Barba ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Comorbidity; COPD; Marker; Mortality

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; OXYGEN;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; LUNG GAS EXCHANGE; MORTALITY; NUTRITIONAL STATUS; OXIDATIVE STRESS; OXYGEN THERAPY; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; SKELETAL MUSCLE;

HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 72149083359     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(09)72856-X     Document Type: Article

References (76)

1. Pauwels R.A., Buist A.S., Calverley P.M.A., Jenkins C.R., and Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global iniciative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 163 (2001) 1256-1276
2. Celli B.R., Cote C.G., Marin J.M., Casanova C., Montes de Oca M., Mendez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 1005-1012
3. Fletcher C., and Peto R. The natural history of chronic bronchitis and emphysema (1976), Oxford University, London
4. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., Connett J.E., and The Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
5. Anthonisen N.R., Wright E.C., and Hodgkin J.E. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 133 (1986) 14-20
6. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320 (2000) 1297-1303
7. Pauwels R.A., Löfdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Longterm treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340 (1999) 1948-1953
8. Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jenkins C.R., Jones P.W., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178 (2008) 332-338
9. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
10. Nocturnal Oxygen Therapy Trial. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease (a clinical trial). Ann Inter Med 93 (1980) 391-398
11. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1 (1981) 681-685
12. Chailleux E., Laaban J.P., and Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 123 (2003) 1460-1466
13. O'Donnell D.E., Revill S.M., and Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 (2001) 770-777
14. Casanova C., Cote C., De Torres J.P., Aguirre-Jaime A., Marin J.M., Pinto-Plata V., et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 (2005) 591-597
15. O'Donnell D.E., Flüge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
16. O'Donnell D.E., Sciurba F., Celli B., Mahler D.A., Webb K.A., Kalberg C.J., et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 130 (2006) 647-656
17. Fishman A., Martinez F., Naunheim K., Piantadosi S., Wise R., Ries A., et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348 (2003) 2059-2073
18. Cooper R., Ghali J., Simmons B.E., and Castaner A. Elevated pulmonary artery pressure. Chest 99 (1991) 112-120
19. Oswald-Mammosser M., Weitzenblum E., Quoix E., Moser G., Chaouat A., and Charpentier C. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 107 (1995) 1193-1198
20. Barbera J.A., Peinado V.I., and Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 892-905
21. Weitzenblum E., Sautegeau A., Ehrhart M., Mammosser M., and Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 131 (1985) 493-498
22. Selinger S.R., Kennedy T.P., and Buescher P. Effects of removing oxygen from patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 136 (1987) 85-91
23. Burgess M.I., Mogulkoc N., Bright-Thomas R.J., Bishop P., Egan J.J., and Ray S.G. Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic obstructive pulmonary disease. J Am Soc Echocardiogr 15 (2002) 633-639
24. Incalzi R.A., Fuso L., De Rosa M., Di Napoli A., Basso S., Pagliari G., et al. Electrocardiographic signs of chronic cor pulmonale: a negative prognostic findings in chronic obstructive pulmonary disease. Circulation 99 (1999) 1600-1605
25. Kanner R.E., Connett J.E., Williams D.E., Buist A.S., and The Lung Health Study Research Group. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in the Lung Health Study. Am J Med 106 (1999) 410-416
26. Scanlon P.D., Connett J.E., Walter L.A., Altose M.D., Bailey W.C., and Buist A.C. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000) 381-390
27. Oga T., Nishimura K., Tsukino M., Sato S., and Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Role of exercise capacity and health status. Am J Respir Crit Care Med 167 (2003) 544-549
28. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., Connett J.E., et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
29. Vestbo J., Prescott E., Almdal T., Dahl M., Nordestgaard B.G., Andersen T., et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 173 (2006) 79-83
30. Schols A.M., Slangen J., Volovics L., and Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998) 1791-1797
31. Soler J.J., Sanchez L., Roman P., Martinez M.A., and Perpiñá M. Prevalencia de desnutrición en pacientes con EPOC estable. Arch Bronconeumol 40 (2004) 250-258
32. Agusti A.G., Noguera A., Sauleda J., Sala E., Pons J., and Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 347-360
33. Nici L. Mechanisms and measures of exercise intolerance in chronic obstructive pulmonary disease. Clin Chest Med 21 (2000) 693-704
34. Pinto-Plata V.M., Cote C., Cabral H., Taylor J., and Celli B.R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 23 (2004) 28-33
35. Oga T., Nishimura K., Tsukino M., Sato S., and Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 167 (2003) 544-549
36. Cote C.G., and Celli B.R. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 26 (2005) 630-636
37. Nishimura K., Izumi T., Tsukino M., and Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121 (2002) 1434-1440
38. Domingo-Salvany A., Lamarca R., Ferrer M., Garcia-Aymerich J., Alonso J., Félez M., et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002) 680-685
39. Van den Boom G., Rutten-van Molken M.P., Tirimanna P.R., van Schayck C.P., Folgering H., and van Weel C. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J 11 (1998) 67-72
40. Orens J.B., Estenne M., Arcasoy S., Conte J.V., Corris P., Egan J.J., et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25 (2006) 745-755
41. Soler-Cataluña J.J., Martínez-García M.A., Román Sánchez P., Salcedo E., Navarro M., and Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (2005) 925-931
42. Soler Cataluña J.J., Martínez García M.A., Sánchez L., and Román P. Valor pronóstico del índice e-BODE (exacerbaciones graves y BODE) en la EPOC. Arch Bronconeumol 43 (2007) 63-64
43. Rodriguez Roisin R. Toward a consensus definition for COPD exacerbations. Chest 117 (2000) 398S-401S
44. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., and Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-204
45. Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., and Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998) 1418-1422
46. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320 (2000) 1297-1303
47. Donaldson G.C., Seemungal T.A., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002) 847-852
48. MacCallum P.K. Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. Proc Am Thorac Soc 2 (2005) 34-43
49. De Torres J.P., Cordoba Lanus E., López Aguilar C., Muros de Fuentes M., Montejo de Garcini A., Aguirre Jaime A., et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 27 (2006) 902-907
50. Joppa P., Petrasova D., Stancak B., and Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 130 (2006) 326-333
51. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
52. Man S.F., and Sin D.D. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 (2005) 78-82
53. Sin D.D., Lacy P., York E., and Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004) 760-765
54. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. Creactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007) 250-255
55. Keatings V.M., Collins P.D., Scott D.M., and Barnes P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153 (1996) 530-534
56. Aaron S.D., Angel J.B., Lunau M., Wright K., Fex C., Le Saux N., et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163 (2001) 349-355
57. De Godoy I., Donahoe M., Calhoun W.J., Mancino J., and Rogers R.M. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 153 (1996) 633-637
58. Casanova Macario C., De Torres Tajes J.P., and Montes de Oca M. Aspectos sistémicos y factores pronósticos. Arch Broncocneumol 43 Supl 3 (2007) 25-34
59. Van Helvoort H.A., Heijdra Y.F., Thijs H.M., Viña J., Wanten G.J., and Dekhuijzen P.N. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 38 (2006) 1543-1552
60. Schols A.M., Buurman W.A., Staal van den Brekel A.J., Dentener M.A., and Wouters E.F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51 (1996) 819-824
61. Antón Díaz E., Ruíz López D., and Ancochea Bermúdez J. Herencia y ambiente en la EPOC. Arch Bronconeumol 43 Supl 1 (2007) 10-17
62. Van der Vaart H., Postma D.S., Timens W., Hylkema M.N., Willemse B.W., Boezen H.M., et al. Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res 6 (2005) 22-33
63. McCrea K.A., Ensor J.E., Nall K., Bleecker E.R., and Hasday J.D. Altered cytokine regulation in the lungs of cigarette smokers. Am J Respir Crit Care Med 150 (1994) 696-703
64. Wood A.M., and Stockley R.A. The genetics of chronic obstructive pulmonary disease. Respir Res 7 (2006) 130-144
65. Jakobsson P., Jorfeldt L., and Brundin A. Skeletal muscle metabolites and fiber types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur Respir J 3 (1990) 192-196
66. Agustí A.G., Sauleda J., Miralles C., Gomez C., Togores B., Sala E., et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002) 485-489
67. Thompson P.D., Buchner D., Piña I.L., Balady G.J., Williams M.A., Macus B.H., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. Circulation 107 (2003) 3109-3116
68. Montes de Oca M., Torres S.H., González Y., Romero E., Hernández N., and Tálamo C. Cambios en la tolerancia al ejercicio, calidad de vida relacionada con la salud y características de los músculos periféricos después de 6 semanas de entrenamiento en pacientes con EPOC. Arch Bronconeumol 41 (2005) 413-418
69. Puente Maestu L., Tena T., Trascasa C., Pérez Parra J., Godoy R., García M.J., et al. Training improves muscle oxidative capacity and oxygenation recovery kinetics in patients with chronic obstructive pulmonary disease. Eur J Appl Physiol 88 (2003) 580-587
70. Gea J., and Barreiro E. Update on the mechanisms of muscle dysfunction in COPD. Arch Bronconeumol 44 (2008) 328-337
71. Chatila W.M., Thomashow B.M., Minai O.A., Criner G.J., and Make B.J. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (2008) 549-555
72. De Miguel Díez J., and Méndez Bailón M. Comorbilidad en la EPOC. Implicaciones diagnósticas y terapéuticas. Rev Patol Respir 11 Supl 2 (2008) 109-116
73. Soriano J.B., Visick G.T., Muellerova H., Payvandi N., and Hansell A.L. Patterns of comorbilities in newly diagnosed COPD and asthma in primary care. Chest 128 (2005) 2099-2107
74. Almagro P. Factores pronósticos en la EPOC. El papel de la comorbilidad. Rev Clin Esp 207 Supl 1 (2007) 8-13
75. De Miguel Díez J., Izquierdo Alonso J.L., Molina París J., Bellón Cano J.M., Rodríguez González-Moro J.M., and De Lucas Ramos P. Factores determinantes de la prescripción farmacológica en los pacientes con EPOC estable. Resultados de un estudio multicéntrico español (IDENTEPOC). Arch Bronconeumol 41 (2005) 63-70
76. Escarrabill J. Costes sanitarios de la enfermedad pulmonar obstructiva crónica (EPOC). Arch Bronconeumol 39 (2003) 435-436